02/09/2021
Cleveland Diagnostics Raises $19.4M
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has closed a Series D round of $17.4 million. The round was led by LYFE Capital, with participation from existing investors including Cleveland Clinic and others. Following the close of the round, the company received a term sheet for a $2M convertible note, expected to close shortly. Funds raised will be used to expand commercialization of IsoPSA—the company’s first diagnostic test, designed to enhance early detection of prostate cancer—as well as to expand internal infrastructure and operations to support platform development for other tests, including breast and lung cancer.
02/09/2021
Eurofins Viracor, Cleveland Clinic Sign License Deal for Kidney Transplant Rejection Biomarker Test
Diagnostics company Eurofins Viracor said on Monday that it has signed a licensing agreement with the Cleveland Clinic for exclusive rights to a urine biomarker test for detecting rejection in kidney transplant patients.
02/09/2021
Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS Disorders
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced multi-year collaborations with Cleveland Clinic and UT Southwestern Gene Therapy Program (UTSW) to advance next-generation mini-gene payloads for AAV gene therapies for the treatment of genetic epilepsies and additional CNS disorders.
02/08/2021
Eurofins Viracor, Cleveland Clinic Sign License Deal for Kidney Transplant Rejection Biomarker Test
Diagnostics company Eurofins Viracor said on Monday that it has signed a licensing agreement with the Cleveland Clinic for exclusive rights to a urine biomarker test for detecting rejection in kidney transplant patients.
01/29/2021
Olympus to Acquire Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities
Olympus Corporation (TSE: 7733) today announced that it has entered into an agreement to acquire Quest Photonic Devices B.V. (Quest; CEO: Richard Meester) for up to EUR50 million including milestone payments to strengthen its surgical endoscopy capabilities.
01/29/2021
Cleveland Clinic receives $6.7 million NIH grant to study high-intensity exercise as Alzheimer's prevention
Cleveland Clinic receives $6.7 million NIH grant to study high-intensity exercise as Alzheimer's preventionThe five-year study will assess the effect of home-based indoor cycling in slowing disease progression in healthy older people at high genetic risk for developing Alzheimer's disease.
01/25/2021
Through a $500 Million Partnership with the State of Ohio, JobsOhio and Ohio Development Services Agency, Cleveland Clinic Forms Global Center for Pathogen Research & Human Health
As part of the new Cleveland Innovation District announced today by State of Ohio Governor Mike DeWine, Lieutenant Governor Jon Husted, JobsOhio and Ohio Development Services Agency, Cleveland Clinic will significantly expand its global commitment to infectious disease research and translational programs to form the Global Center for Pathogen Research & Human Health.
01/18/2021
First Case Completed in Feasibility Study of Non-Radiation-Based EVAR Navigation Platform
In December, Cleveland Clinic vascular surgeons successfully completed the first surgical case in the MOTION clinical trial of a new non-radiation-based surgical navigation platform for endovascular aortic interventions.
01/08/2021
Breath-Based Diagnostics Gain Traction as Potential Method for Detecting SARS-CoV-2
As the COVID-19 pandemic has ravaged the globe and strained diagnostic resources, many players have entered or expanded their presence on the scene to interrogate new methods of testing for SARS-CoV-2.
One of those methods is the use of breath samples for diagnosing the virus, and a variety of companies and research teams from around the world are developing tests that seek to detect SARS-CoV-2 in the breath, although no such test has received Emergency Use Authorization from the US Food and Drug Administration.
12/30/2020
Top 10 Medical Innovations for 2021
COVID-19 has dominated headlines for months, but science continues to move medicine forward, beyond the pandemic. According to Cleveland Clinic’s annual ranking of medical innovations, expanded access to medications for cystic fibrosis and hepatitis c, take two of the top ten spots.